The historical rank and industry rank for Microba Life Sciences's Net Margin % or its related term are showing as below:
FRA:F3Y'
s Net Margin % Range Over the Past 10 Years
Min: -244.62 Med: -199.43 Max: -95.34
Current: -132.53
FRA:F3Y's Net Margin % is ranked worse than 81.86% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.56
vs FRA:F3Y: -132.53
Microba Life Sciences (FRA:F3Y) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Microba Life Sciences Net Margin % Related Terms
Microba Life Sciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F3Y vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (FRA:F3Y) has a Net Margin % of -144.20% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Microba Life Sciences and its competitors. According to the industry distribution chart, Microba Life Sciences ranks #167 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 81.9%.
Is Microba Life Sciences' Net Margin % too high?
Microba Life Sciences' current Net Margin % is -144.20%. Based on the distribution chart, Microba Life Sciences ranks #167 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Microba Life Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Microba Life Sciences' Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #167 out of 204 companies for Net Margin %. This places Microba Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Microba Life Sciences and its competitors. Microba Life Sciences's current Net Margin % is -144.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Microba Life Sciences (FRA:F3Y) has a current Net Margin % of -144.20%. The stock's GF Value™ is €0.12, compared to a current price of €0.02 — trading 85.4% below its estimated fair value. The current Net Margin % is -144.20%. Microba Life Sciences' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Microba Life Sciences (FRA:F3Y), the current Net Margin % is -144.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microba Life Sciences (FRA:F3Y) Overvalued in 2026?
Based on GuruFocus' analysis, Microba Life Sciences stock appears to be undervalued.
The current stock price of €0.02 is trading 85.4% below its estimated GF Value™ of €0.12.
Key valuation signals for FRA:F3Y:
Net Margin %: -144.20%
GF Value™: €0.12 vs. price of €0.02 (85.4% below fair value)
No single metric tells the full story. See the FRA:F3Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
29GF Score
Get the complete analysis for FRA:F3Y
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F3Y has been successfully added to your 
